Clinical trials: 5-FU
Rectal Cancer
Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
The purpose of the research is to evaluate whether both chemotherapy and radiotherapy can lead to higher rates of clinical complete response leading to organ preservation in human subjects with cancer.
- Trial name
- NCT04380337
- Testing
- FOLFOXIRI, FOLFOX regimen, XELOX
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Stanford University
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
- Trial name
- NCT00227617
- Testing
- bevacizumab, 5-fluorouracil, leucovorin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Francisco
Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
The purpose of the study is to determine the most tolerable and safe dose of ZD6474 (Zactima, Vandetanib) when given with standard chemotherapy, radiation therapy and surgery in patients with cancer of the esophagus
- Conditions
- Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Cancer of the Stomach
- Trial name
- NCT01183559
- Testing
- Vandetanib, 5 Fluorouracil (FU), Carboplatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Fox Chase Cancer Center
Breast Cancer
Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways after surgery may kill more tumor cells.
- Trial name
- NCT00024102
- Testing
- Standard Treatment, capecitabine
- Where
- 334 sites in United States, Canada and 1 more
- Volunteers
- 633 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Cancer
Radiation w/FOLFIRINOX-Losartan for Pancreatic Cancer
This is a Phase II clinical trial, which tests the safety and effectiveness of an investigational combination of drugs to learn whether the combination of drugs works in treating a specific cancer.
- Trial name
- NCT01821729
- Testing
- FOLFIRINOX, Losartan, Proton Beam Radiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Gastric Adenocarcinoma
Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
This is a study of pembrolizumab (MK-3475) as first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Trial name
- NCT02494583
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Volunteers
- 763 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Cancer
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
This double-blind, placebo-controlled, randomized, multicenter, international, parallel arm study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab, fluoropyrimidine and cisplatin as first-line…
- Trial name
- JACOB (NCT01774786)
- Testing
- 5-Fluorouracil, Capecitabine, Cisplatin
- Where
- 172 sites in United States, Australia and 30 more
- Volunteers
- 780 people
- Sponsor
- Hoffmann-La Roche
Head and Neck Cancer
Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer
The main purpose of this study is to explore and compare the efficacy of Cetuximab (ERBITUX®) added to two concurrent chemoradiotherapy platforms of different intensity in locally advanced head and neck cancer.
- Trial name
- EPIC (NCT00468169)
- Testing
- Cetuximab, 5-FU, Hydroxyurea
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Chicago
Carcinoma, Hepatocellular
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
The main purpose of this study is to determine if the advised dose of ramucirumab is safe to be taken with chemotherapy treatment in participants with advanced liver tumors.
- Trial name
- NCT02069041
- Testing
- Ramucirumab, FOLFOX4
- Where
- 3 sites in Taiwan
- Volunteers
- 8 people
- Sponsor
- Eli Lilly and Company
Colorectal Carcinoma
A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)
The primary objective of this study is to investigate the safety and tolerability of the anti-vascular endothelial growth factor receptor-2 (anti-VEGFR-2) monoclonal antibody Ramucirumab (IMC-1121B) in combination with…
- Trial name
- NCT01286818
- Testing
- Ramucirumab (IMC-1121B), Irinotecan, levofolinate
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer
Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00002525
- Testing
- fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 859 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Ovarian Cancer, Basal Cell Carcinoma
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent…
- Conditions
- Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
- Trial name
- NCT00959647
- Testing
- Vismodegib, FOLFOX, FOLFIRI
- Where
- 10 sites in United States
- Volunteers
- 19 people
- Sponsor
- Genentech, Inc.
Esophageal Cancer
Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer
Esophageal cancer is a highly aggressive tumor. Treatment options are various and range from chemotherapy to radiotherapy and several surgical techniques. Nevertheless, the overall survival rates for this disease remain poor.
- Trial name
- NCT01787006
- Testing
- Cetuximab, Cisplatin, 5-FU, Radiotherapy
- Where
- Germany
- Volunteers
- 74 people
- Sponsor
- University Hospital Schleswig-Holstein
Gastric Cancer
Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer
Primary Objective: To compare the 3-year progression free survival (PFS) in the two treatment arms. Secondary Objectives: Overall survival (OS). Postoperative pathological stage and R0 (complete) resection rate.
- Trial name
- PRODIGY (NCT01515748)
- Testing
- Docetaxel (XRP6976), Oxaliplatin (SR96669), S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)
- Where
- South Korea
- Volunteers
- 530 people
- Sponsor
- Sanofi
Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer
Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)
Drugs used against cancer work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- CRYSTAL (NCT00154102)
- Testing
- Cetuximab, FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
- Where
- 154 sites in Argentina, Australia and 28 more
- Volunteers
- 1,221 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Squamous Cell Carcinoma of the Head and Neck
A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck
The primary objective of this trial is to assess the antitumor activity and safety profile of cetuximab when given in combination with cisplatin + 5-Fluorouracil (5-FU) for the first-line treatment of recurrent and/or metastatic…
- Trial name
- CHANGE (NCT01177956)
- Testing
- Cetuximab, Cisplatin, 5-Fluorouracil
- Where
- 14 sites in China, South Korea
- Volunteers
- 73 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352105
- Testing
- cisplatin, fluorouracil, Iressa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- David Adelstein
Colon Cancer, Rectal Cancer
A Study of Ramucirumab or Icrucumab in Colorectal Cancer
The purpose of this study is to determine if participants with metastatic colorectal cancer live longer without their cancer progressing when treated with standard chemotherapy, standard chemotherapy plus ramucirumab, or standard…
- Trial name
- NCT01111604
- Testing
- Ramucirumab, Icrucumab, mFOLFOX-6
- Where
- 17 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- Eli Lilly and Company
Cancer, Colon Cancer
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
This is a multi-center, open-label, randomized, phase 2, two-arm clinical trial to be conducted in the United States. Approximately 210 eligible KRAS wild-type expressing metastatic colorectal cancer subjects who have failed…
- Conditions
- Cancer, Colon Cancer, Colorectal Cancer, Metastatic Cancer
- Trial name
- NCT00418938
- Testing
- Panitumumab, Bevacizumab, Leucovorin
- Volunteers
- 266 people
- Sponsor
- Amgen
Pancreatic Cancer
Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer
The intention of this trial is to determine the maximum tolerated of the treatment combination and to evaluate its safety and efficacy.
- Trial name
- NCT00463840
- Testing
- Oxaliplatin, 5FU, Radiation
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- NYU Langone Health